Aurora A Kinase Is a Priority Pharmaceutical Target for the Treatment of Cancers

• Published in: Trends in pharmacological sciences (Regular ed.) Vol. 38; no. 8; pp. 687 - 700
• Main Authors: Damodaran, Arun Prasath, Vaufrey, Lucie, Gavard, Olivia, Prigent, Claude
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.08.2017; Elsevier
• Subjects: Advanced Basic Science; Animals; Aurora; Aurora Kinase A - antagonists & inhibitors; cancer; Genetics; Humans; inhibitors; kinase; Life Sciences; Molecular Targeted Therapy; Neoplasms - drug therapy; Neoplasms - enzymology; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Aurora; inhibitors; kinase; cancer
• ISSN: 0165-6147; 1873-3735
• DOI: 10.1016/j.tips.2017.05.003

Aurora kinases control multiple events during cell cycle progression and are essential for mitotic and meiotic bipolar spindle assembly and function. There are three Aurora kinases in mammals, some of which have oncogenic properties and all of which are overexpressed in multiple cancers. Pharmaceutical companies quickly made these kinases priority targets for the development of inhibitors to be used as cancer treatments. In this review, we focus on Aurora A, against which several inhibiting compounds have been discovered and made available; however, even though some of these compounds underwent clinical trials, none have yet gone beyond Phase III trials. The varying efficiencies and particularities of these drugs raise several questions that are explored in this review: is Aurora A even a good target? What biomarkers can we use to measure its activity in vivo ? How can we improve the Aurora A-inhibiting drugs?